Abbott Raises 2026 Profit Forecast on Diagnostics and Heart Devices

By EC Assets · Published 16 July 2026

Abbott Laboratories has increased its profit forecast for 2026. This revised outlook is driven by strong performance in its diagnostics and heart device businesses. The company previously issued guidance for the current fiscal year. The company's diagnostics segment involves various testing products and services. Its heart device portfolio includes a range of medical technologies for cardiovascular conditions. These areas have shown significant strength, contributing to the elevated profit expectations. In the broader healthcare sector, the iShares Global Healthcare ETF has outperformed the Invesco Health Care ETF in 2026. This indicates varying performance across different investment vehicles tracking the healthcare industry. Vickers data on top buyers and sellers was also released for July 16, 2026. Brazil's retail sales in May rose by 0.1%. This increase missed forecasts. TSMC has raised its capital expenditure and revenue forecast, demand for artificial intelligence chips. This article is intended for informational purposes only. It does not constitute investment advice.